Standout Papers

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic... 2019 2026 2021 2023 302
  1. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer (2019)
    Shaveta Vinayak, Sara M. Tolaney et al. JAMA Oncology

Immediate Impact

3 from Science/Nature 70 standout
Sub-graph 1 of 22

Citing Papers

New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Colorimetric sensing for translational applications: from colorants to mechanisms
2024 Standout
3 intermediate papers

Works of Corrine Zarwan being referenced

Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).
2020
Selective Blockade of Matrix Metalloprotease-14 with a Monoclonal Antibody Abrogates Invasion, Angiogenesis, and Tumor Growth in Ovarian Cancer
2013

Author Peers

Author Last Decade Papers Cites
Corrine Zarwan 671 219 197 316 27 1.1k
Jorge Chaves 886 273 354 203 41 1.1k
Jean‐Christophe Sabourin 721 227 415 487 28 1.4k
Gregory Friberg 715 88 310 498 35 1.2k
Tiffany G. Huynh 748 103 560 374 20 1.2k
Antonio Febbraro 636 106 310 245 56 1.2k
Kirsten Kübler 333 272 71 341 27 905
Sanjeeve Balasubramaniam 444 174 147 272 33 894
Keisuke Kurose 309 92 127 627 28 1.0k
Ewan Brown 495 269 130 503 29 1.1k
Catherine Shannon 681 65 280 141 48 1.1k

All Works

Loading papers...

Rankless by CCL
2026